A landmark randomized, placebo-controlled trial provides the clearest evidence to date that shunt surgery benefits patients with idiopathic normal-pressure hydrocephalus (iNPH), a condition long ...
This article deconstructs the IIH guidelines, contrasting medical management (acetazolamide, topiramate) with the practical ...
Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...
After tube-shunt surgery, the choices for further surgical intervention are often limited, because the conjunctiva may be scarred and not amenable to further manipulation. Such interventions as ...
Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical data on VisiPlate® Aqueous Shunt from the VITA Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback